Ginkgo Bioworks Holdings, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NYSE
Ginkgo Bioworks Holdings, Inc. reported a significant revenue decrease in Q3 2025 and for the nine months ended September 30, 2025, as it continues its comprehensive restructuring plan.
NYSE
Ginkgo Bioworks Holdings, Inc. reported a significant reduction in net and operating losses for Q2 and H1 2025, driven by ongoing restructuring efforts and expense reductions, despite a decline in Biosecurity revenue.
NYSE
10-Q: Ginkgo Bioworks Reports Q1 2025 Results, Revenue Increases Driven by BiomEdit Contract Termination
Ginkgo Bioworks' Q1 2025 revenue increased due to a one-time revenue recognition from the BiomEdit contract termination, while the company continues to manage restructuring and cost-saving initiatives.
NYSE
Ginkgo Bioworks saw a significant increase in Cell Engineering revenue in Q3 2024, while also reporting a net loss and restructuring charges.
NYSE
Ginkgo Bioworks reported a net loss of $217.2 million for Q2 2024, alongside a restructuring plan aimed at reducing operational expenditures.
NYSE
Ginkgo Bioworks' first quarter 2024 results show a decrease in revenue compared to the same period last year, driven by a strategic shift in its biosecurity business and timing of cell engineering programs.